Bioethics Blogs

Increasing Access to Biosimilar Drugs

The development of ‘specialty drugs’
in the health care industry has created legal, ethical, and public policy
issues because patients are not able to get access to their prescribed
medications based on the expense.  Specialty
drugs are usually biologicals, treat serious conditions, and  are very expensive with no cheap
alternatives.

Source: Bioethics Today, the blog of the Alden March Bioethics Institute.

The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.